TOLERANZIA AB
Toleranzia develops drugs that utilize the immune system's own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the disease cause, can cure or greatly alleviate the disease and not just reduce the symptoms that current treatments do. The company's drug candidate, TOL2, is developed for the autoimmune nerve and muscle disease myasthenia gravis.
TOLERANZIA AB
Industry:
Business Development Pharmaceutical
Founded:
2011-01-01
Address:
Gothenburg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.toleranzia.se
Total Employee:
1+
Status:
Active
Contact:
+46-763-19 98 98
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Current Employees Featured
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Toleranzia AB
Official Site Inspections
http://www.toleranzia.se
- Host name: uke.oderland.com
- IP address: 91.201.61.217
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Toleranzia AB"
Harnessing the power of the immune system | Toleranzia AB
Nov 25, 2024 Toleranzia develops drugs that use the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can …See details»
Corporate governance - Toleranzia AB
Jun 19, 2024 SE-401 82 Göteborg Sweden. Certified Adviser. Mangold Fondkommission AB Tel: +46 (0)8 503 015 50 E-mail: [email protected]. Nomination Committee. Nomination Committee …See details»
Management - Toleranzia AB
Fribert has thus considerable experience both in Toleranzia’s therapy area and in the effective development of small life science companies. CEO since 2016. Holdings: 277 278 shares …See details»
Annual Report 2019 - toleranzia.se
1 Annual Report 2019 Org.nr. 556877‐2866 │ www.toleranzia.se │ Erik Dahlbergsgatan 11 A, 411 26 GothenburgSee details»
Toleranzia AB - LinkedIn
Toleranzia AB | 1,045 followers on LinkedIn. Tämjer kraften i immunsystemet | Toleranzia develops protein-based antigen-specific immune tolerogens to cure patients with autoimmune …See details»
Double recognition of Toleranzia AB
E-mail: [email protected]. About Toleranzia: Toleranzia is an R&D company that builds on a research idea that started its commercial track in 2008 as a project within …See details»
Toleranzia AB - Crunchbase Company Profile & Funding
Toleranzia develops drugs that utilize the immune system's own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the disease cause, can cure or greatly …See details»
Toleranzia - Mangold Fondkommission AB
Oct 30, 2024 Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology …See details»
Report on the annual accounts - toleranzia.se
We have audited the annual accounts of Toleranzia AB decisions of users taken on the basis of these annual (publ), for the year 2022. The annual accounts of the company are included on …See details»
Toleranzia AB – Year-End Report 2023 - Toleranzia AB
Feb 23, 2024 The "Company" or "Toleranzia" refers to Toleranzia AB with organization number 556877-2866. ... Vi använder cookies för att se till att vi ger dig den bästa upplevelsen på vår …See details»
Toleranzia Company Profile - Office Locations, Competitors ... - Craft
Toleranzia is a company specializing in preclinical and early clinical drug research for autoimmune diseases. It develops drugs that utilize the immune system’s own intrinsic power. The …See details»
Toleranzia AB appoints SKMG as new Certified Adviser (MFN)
4 days ago Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, [email protected], is the company's Certified Adviser. …See details»
Toleranzia AB – Year-End Report 2022
Feb 24, 2023 ”Company” or ”Toleranzia” relates to Toleranzia AB with Swedish registration number 556877-2866. ... In 2022, the company has added human resources equivalent to …See details»
Toleranzia AB
Toleranzia AB | 556877-2866. 2 Interim report Toleranzia AB First quarter 2022 . First quarter, 1 January – 31 March • Net sales 0 SEK (0 SEK). • Profit/loss after financial items -2 071 922 …See details»
Toleranzia AB: Interim report 2022-01-01 – 2022-06-30 - Placera
Aug 26, 2022 A research consortium in which Toleranzia participates as an industrial partner was granted support from the Swedish Knowledge Foundation (KK-stiftelsen). The project will …See details»
Toleranzia AB appoints SKMG as new Certified Adviser
4 days ago Toleranzia AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding the service as Certified Adviser. SKMG …See details»
Toleranzia AB: Interim report third quarter 2024
Oct 21, 2024 The "Company" or "Toleranzia" refers to Toleranzia AB with organization number 56877-2866. ... Vi använder cookies för att se till att vi ger dig den bästa upplevelsen på vår …See details»
Orphan Drug Designation granted by FDA - Toleranzia
The approval from the FDA is a great acknowledgement of Toleranzia and of its technology platform, says Toleranzias Executive Chairman of the Board Elisabet Litsmark Nordenstam. …See details»
Toleranzia AB publishes the Nomination Committee - MFN.se
Nov 25, 2024 Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, [email protected], is the company's Certified …See details»
Toleranzia AB: Interim report 2022-01-01 – 2022-09-30
Jan 1, 2022 ”Company” or ”Toleranzia” relates to Toleranzia AB with Swedish registration number 556877-2866. Significant events during the third quarter 2022. Toleranzia initiated a …See details»